Good
Partially Aligned
Patient Risk:
Low
Summary
Most claims align directionally with labeled indications and safety warnings/precautions (e.g., cardiovascular, heart failure, CKD; genitourinary infections; volume depletion/hypotension risk; ketoacidosis warning; lower-limb amputation precaution). However, several claims are too vague or framed as “commonly discussed in consumer-facing materials” and include details not explicitly present in the provided label excerpts (e.g., “normal-ish blood sugar” framing; amputation “class conversation” phrasing; attribution to consumer ads).
Category Scores
Accurate Statements
Jardiance is promoted for type 2 diabetes.
Indications and Usage: adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.
Jardiance has also been promoted for heart and kidney outcomes in relevant patients.
Indications and Usage: (1) reduce risk of cardiovascular death and hospitalization for heart failure in adults with heart failure; (2) reduce risk of sustained decline in eGFR, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression.
Genital yeast infections are a commonly discussed Jardiance-related risk in consumer-facing materials.
Warnings and Precautions 5.3: increases risk of genitourinary infections including urinary tract infections and genital mycotic infections (genital fungal infections).
Urinary tract infections are a commonly discussed Jardiance-related risk in consumer-facing materials.
Warnings and Precautions 5.3: increases risk of genitourinary infections including urinary tract infections...
Dehydration/low blood pressure is a commonly discussed Jardiance-related risk, especially in people on diuretics.
Warnings and Precautions 5.2: volume depletion which may manifest as symptomatic hypotension; patients on loop diuretics may be at increased risk.
Diabetic ketoacidosis can occur even with normal-ish blood sugar, per standard prescribing warnings.
Warnings and Precautions 5.1: increased risk of diabetic ketoacidosis; risk factors and precipitating conditions listed; ketone monitoring/assessment guidance.
There has been a broader class conversation about increased risk of amputations and other lower-limb issues with SGLT2 inhibitors, with specific details depending on labeling and patient risk factors.
Warnings and Precautions 5.5: in some clinical studies with SGLT2 inhibitors, an imbalance in the incidence of lower limb amputation has been observed; counsel and monitor for diabetic foot infection.
Unsupported Statements
Consumer-facing ads for Jardiance include brief safety information.
No consumer advertising/consumer-facing materials content is present in the provided prescribing information excerpts.
Genital yeast infections are a commonly discussed Jardiance-related risk in consumer-facing materials.
The label excerpt supports the risk category (genital mycotic infections) but does not support claims about what is “commonly discussed” in consumer-facing materials.
Urinary tract infections are a commonly discussed Jardiance-related risk in consumer-facing materials.
The label excerpt supports urinary tract infection risk but does not support claims about what is “commonly discussed” in consumer-facing materials.
Dehydration/low blood pressure is a commonly discussed Jardiance-related risk, especially in people on diuretics.
The label excerpt supports volume depletion/hypotension risk and increased risk with loop diuretics, but does not support “commonly discussed” or consumer-material framing.
Diabetic ketoacidosis can occur even with normal-ish blood sugar, per standard prescribing warnings.
Provided label excerpt discusses ketoacidosis risk, precipitating conditions, and ketone monitoring, but the specific “normal-ish blood sugar” phrasing is not present in the excerpt.
There has been a broader class conversation about increased risk of amputations and other lower-limb issues with SGLT2 inhibitors, with specific details depending on labeling and patient risk factors.
The label excerpt supports the existence of an imbalance in lower limb amputation in some clinical studies with SGLT2 inhibitors, but does not support the broader “class conversation” framing or “other lower-limb issues” beyond what is explicitly described.
Contradictions
Low
AI Statement
Label Reference
Important Omissions
If evaluating the implied safety messaging accuracy, the label excerpt specifically includes additional details for ketoacidosis risk factors and monitoring/withholding instructions (e.g., assess ketones, withhold for temporary clinical situations), which are not reflected in the AI claims beyond general risk mention.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The safety topics mentioned (genitourinary mycotic infections/UTIs, volume depletion/hypotension risk with diuretics, ketoacidosis risk, and lower-limb amputation precaution) are directionally consistent with label warnings/precautions. Patient risk is limited by lack of dosing/clinical instruction errors, but some statements are unsupported due to consumer-material claims and unverifiable phrasing (e.g., “normal-ish blood sugar”).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several claims reference consumer-facing ad content (“commonly discussed”) and use non-label phrasing (e.g., “normal-ish blood sugar”) that is not supported by the provided prescribing information excerpts.
Suggested Improvement
Rephrase consumer-material assertions as label-supported risk topics (e.g., “genital mycotic infections and UTIs are risks described in the prescribing information”) and avoid unsupported specificity not present in the label excerpt (e.g., remove “normal-ish blood sugar” unless directly supported). For amputation, stick to the label’s stated precaution about lower-limb amputation imbalance and routine preventative foot care/monitoring.